Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 3/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | PTGFR | P43088 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114477 | 1.00 | ALOX5 (0.38) | ALOX5PRKCAPRKCEHPSETLR4 | |
| SCHEMBL1975012 | 0.83 | LPAR1 (0.33) | PRKCAPRKCELPAR1ALDH1A1 | |
| SCHEMBL1975014 | 0.83 | LPAR1 (0.33) | PRKCAPRKCELPAR1ALDH1A1 | |
| SCHEMBL1114915 | 0.79 | — | — | |
| SCHEMBL1114618 | 0.79 | TRPV1 (0.37) | ALOX5TRPV1 | |
| SCHEMBL658527 | 0.78 | ALOX5 (0.40) | ALOX5PRKCAPRKCEHPSETBXA2R | |
| SCHEMBL658528 | 0.78 | ALOX5 (0.39) | ALOX5PRKCAPRKCEHPSELPAR1 | |
| SCHEMBL29255772 | 0.78 | ALOX5 (0.58) | ALOX5HPSELPAR1LPAR3ALDH1A1 | |
| SCHEMBL657946 | 0.77 | ALOX5 (0.44) | ALOX5PRKCAPRKCEHPSETBXA2R | |
| SCHEMBL657947 | 0.77 | ALOX5 (0.44) | ALOX5PRKCAPRKCEHPSETBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150981-A1 | Compounds for Use in Therapy | BANGOR UNIVERSITY (GB) | 2011-06-23 | — | — | US | disclosed |
| US-20110142916-A1 | Adjuvants for Use in Vaccination | BANGOR UNIVERSITY (GB) | 2011-06-16 | — | — | US | disclosed |
| EP-2278995-A2 | COMPOUNDS FOR USE IN THERAPY | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-2278996-A1 | ADJUVANTS FOR USE IN VACCINATION | Bangor University (GB) | 2011-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142916-A1 | Adjuvants for Use in Vaccination | NR1H3, NR1H2, INTS6 | ALOX5 663/4885PRKCA 2731/4885PRKCE 2108/4885 |
| US-20110150981-A1 | Compounds for Use in Therapy | CD4, MSR1, TST | ALOX5 186/4885PRKCA 3262/4885PRKCE 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.